Vertex appoints Atkinson EVP Chief Technical Operations Officer
Vertex Pharmaceuticals (NASDAQ:VRTX) has announced that E. Morrey Atkinson, Ph.D., has been appointed Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations, effective immediately.
Dr. Atkinson has served as Senior Vice President of Global Commercial Manufacturing and Supply Chain since July 2020.

Prior to joining Vertex, Dr. Atkinson held various roles of increasing responsibility at Eli Lilly, Cook Pharmica, and most recently Bristol Myers Squibb, where he served as Senior Vice President of Global Manufacturing Operations.


More on Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated 2023 Q2 - Results - Earnings Call Presentation
Vertex Pharmaceuticals Still Looks Attractive
Vertex: Continued Advances In Cystic Fibrosis Market With Expansion Plans
Vertex Pharmaceuticals: Strategically Positioning For Future Success
Bluebird bio favored at Baird as sickle cell disease space gets busy
Vertex/CRISPR, bluebird sickle cell therapies could be cost-effective - ICER
Vertex Pharmaceuticals Q2 2023 Earnings Preview
CRISPR, Vertex gain as FDA starts review for gene edited therapy
Seeking Alphaâs Quant Rating on Vertex Pharmaceuticals
Earnings data for Vertex Pharmaceuticals
Dividend for Vertex Pharmaceuticals